Open Access

Single‑blinded, randomized, and controlled clinical trial evaluating the effects of Omega‑3 fatty acids among septic patients with intestinal dysfunction: A pilot study

  • Authors:
    • Huaisheng Chen
    • Wei Wang
    • Yingcai Hong
    • Huadong Zhang
    • Chengying Hong
    • Xueyan Liu
  • View Affiliations

  • Published online on: June 27, 2017     https://doi.org/10.3892/etm.2017.4680
  • Pages: 1505-1511
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sepsis is a systemic inflammatory reaction, which is aggravated by aspects of the immune response that are thought to be inhibited by Omega‑3 fatty acids. The aim of the present study was to determine if Omega‑3 fatty acid could modulate immunological function and improve survival rate among septic patients with intestinal dysfunction. A total of 48 mechanically ventilated patients with intestinal dysfunction were included in this prospective, randomized and single‑blind clinical study. Patients were randomly divided into control (group A) and treatment groups (group B). The treatment protocol for all the participants followed the Sepsis Survival Campaign guidelines, and group B received total parenteral nutrition containing 100 ml of Omega‑3 fatty acids (containing 10 g refined fish oil) per day in addition to the standard treatment applied in group A. Group B had a significantly lower mortality rate compared with group A (12.5 vs. 41.7%, P<0.05) during the 28‑day follow‑up. Group B also had lower Acute Physiology and Chronic Health Evaluation II scores (P<0.05) and lower Marshall scores (P<0.05) at day 7. In addition, group B had a higher ratio of T helper to inducer lymphocytes as well as a higher ratio of CD4 to CD8 lymphocytes (P<0.01 for both) than group A. It was concluded that Omega‑3 fatty acids improved T helper/inducer and CD4/CD8 ratios, and may have reduced mortality, among septic patients with intestinal dysfunction.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen H, Wang W, Hong Y, Zhang H, Hong C and Liu X: Single‑blinded, randomized, and controlled clinical trial evaluating the effects of Omega‑3 fatty acids among septic patients with intestinal dysfunction: A pilot study. Exp Ther Med 14: 1505-1511, 2017
APA
Chen, H., Wang, W., Hong, Y., Zhang, H., Hong, C., & Liu, X. (2017). Single‑blinded, randomized, and controlled clinical trial evaluating the effects of Omega‑3 fatty acids among septic patients with intestinal dysfunction: A pilot study. Experimental and Therapeutic Medicine, 14, 1505-1511. https://doi.org/10.3892/etm.2017.4680
MLA
Chen, H., Wang, W., Hong, Y., Zhang, H., Hong, C., Liu, X."Single‑blinded, randomized, and controlled clinical trial evaluating the effects of Omega‑3 fatty acids among septic patients with intestinal dysfunction: A pilot study". Experimental and Therapeutic Medicine 14.2 (2017): 1505-1511.
Chicago
Chen, H., Wang, W., Hong, Y., Zhang, H., Hong, C., Liu, X."Single‑blinded, randomized, and controlled clinical trial evaluating the effects of Omega‑3 fatty acids among septic patients with intestinal dysfunction: A pilot study". Experimental and Therapeutic Medicine 14, no. 2 (2017): 1505-1511. https://doi.org/10.3892/etm.2017.4680